Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE trial in Type 2 Diabetes
NCT00145925Phase 3Completed
- Sponsor
- The George Institute for Global Health
- Start
- Jun 2001
- Primary completion
- Mar 2008
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of indapamide + perindopril and gliclazide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by The George Institute for Global Health. Primary endpoints: Composite of non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular cause at 5.5 years and Composite of new or substantially worsening nephropathy or microvascular eye disease at 5.5 years. Started Jun 2001; status: completed.
02
Drugs
indapamide + perindoprilgliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00145925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145925.